Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq

Stock Information for Satellos Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Satellos Bioscience Inc.

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
Satellos to Participate in December Investor Conferences
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
Satellos to Participate in November Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.